Literature DB >> 2848486

Group and strain-specific neutralization sites of infectious bursal disease virus defined with monoclonal antibodies.

D B Snyder1, D P Lana, B R Cho, W W Marquardt.   

Abstract

Two somatic cell hybridizations were performed utilizing splenocytes from mice immunized with one or more strains of infectious bursal disease virus (IBDV). Supernatants from hybridoma cell lines were initially screened by the enzyme-linked immunosorbent assay (ELISA) against multiple strains of IBDV. Cell lines that secreted antibodies with ELISA reactivity patterns of interest were cloned, and their monoclonal antibodies (MCAs) were subsequently tested in cross-virus-neutralization tests. Two of the nine MCAs selected exhibited strong neutralizing activity and precipitated IBDV antigens in agar gel precipitin tests as well. MCA B69 significantly neutralized only the cloned D78 strain of IBDV, whereas MCA R63 neutralized all IBDV strains (representing both serotype I and II viruses) against which it was tested. Results of competitive ELISAs that used the R63 and B69 MCAs showed that the two neutralization sites on the D78 strain were not overlapping.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 2848486

Source DB:  PubMed          Journal:  Avian Dis        ISSN： 0005-2086            Impact factor:   1.577


  14 in total

1.  Naturally occurring-neutralizing monoclonal antibody escape variants define the epidemiology of infectious bursal disease viruses in the United States.

Authors:  D B Snyder; V N Vakharia; P K Savage
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

2.  Transcriptional profiling reveals a possible role for the timing of the inflammatory response in determining susceptibility to a viral infection.

Authors:  Thomas Ruby; Catherine Whittaker; David R Withers; Mounira K Chelbi-Alix; Veronique Morin; Anne Oudin; John R Young; Rima Zoorob
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Nucleotide sequence analysis of the serotype-specific epitope of infectious pancreatic necrosis virus.

Authors:  A Pryde; W T Melvin; A L Munro
Journal:  Arch Virol       Date:  1993       Impact factor: 2.574

4.  A recombinant Newcastle disease virus (NDV) expressing VP2 protein of infectious bursal disease virus (IBDV) protects against NDV and IBDV.

Authors:  Zhuhui Huang; Subbiah Elankumaran; Abdul S Yunus; Siba K Samal
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

5.  Biological roles of the major capsid proteins and relationships between the two existing serotypes of infectious bursal disease virus.

Authors:  S K Reddy; A Silim; M J Ratcliffe
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

6.  Epitope mapping of capsid proteins VP2 and VP3 of infectious bursal disease virus.

Authors:  T Yamaguchi; K Iwata; M Kobayashi; M Ogawa; H Fukushi; K Hirai
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

7.  Genetic mechanisms of antigenic variation in infectious bursal disease virus: analysis of a naturally occurring variant virus.

Authors:  D P Lana; C E Beisel; R F Silva
Journal:  Virus Genes       Date:  1992-08       Impact factor: 2.332

8.  Molecular and structural bases for the antigenicity of VP2 of infectious bursal disease virus.

Authors:  Tobias Letzel; Fasseli Coulibaly; Felix A Rey; Bernard Delmas; Erik Jagt; Adriaan A M W van Loon; Egbert Mundt
Journal:  J Virol       Date:  2007-09-19       Impact factor: 5.103

9.  Very virulent infectious bursal disease virus in Egypt: epidemiology, isolation and immunogenicity of classic vaccine.

Authors:  M K Hassan
Journal:  Vet Res Commun       Date:  2004-05       Impact factor: 2.459

10.  Comparison of neutralizing antigens of recent isolates of infections bursal disease virus.

Authors:  S K Reddy; A Silim
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.